Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study

Fares Alsawah, MD BS, MS, Samuel A. Merrill, MD PhD, Paula L. Bockenstedt, MD, Erica L. Campagnaro, MD, Sumana Devata, MD, Scott D. Gitlin, MD, Mark S Kaminski, MD, Alice M. Cusick, MD, Tycel J. Phillips, MD, Suman L. Sood, MD, Moshe Talpaz, MD, Albert Thomas Quiery, MD, Philip S Boonstra, PhD, Asra Z. Ahmed, MD, Ryan A. Wilcox, MD PhD

Blood (2018) 132 (Supplement 1): 1119.

https://doi.org/10.1182/blood-2018-99-116854

Published: 2018

Journal Articles

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom's Macroglobulinemia

Blood (2017) 130 (Supplement 1): 2767.

https://doi.org/10.1182/blood.V130.Suppl_1.2767.2767

Published: 2017

Journal Articles

Management of Catastrophic Antiphosphopholipid Syndrome with Eculizumab

Ami Chitalia, MD, David Swoboda, MD, Catherine Broome, MD

Blood (2016) 128 (22): 2603.

https://doi.org/10.1182/blood.V128.22.2603.2603

Published: 2016

Journal Articles

A Patient with Chronic Lymphocytic Leukemia and Bone Localization: A Case Report

Iolanda Donatella Vincelli, Patrizia Cufari, Said al Sayyad, Carmelo Tuscano, Natale Porta, Claudio di Cristofano, Vincenzo Petrozza, Demetrio Aricò, Caterina Stelitano, Stefania Ciolli, Grazia Iaria, Angela Violi, Francesca Ronco

Blood (2015) 126 (23): 5301.

https://doi.org/10.1182/blood.V126.23.5301.5301

Published: 2015

Journal Articles

Antitumor Activity of Bortezomib (PS-341; Velcade) in a Phase II Study of Patients with Previously Untreated or Treated Waldenstrom’s Macroglobulinemia (WM).

Christine I. Chen, MD, Darrell White, MD, C. Tom Kouroukis, MD, A. Keith Stewart, MD, Kang Howson-Jan, MD, Loree Larratt, MD, Jean Powers, Elizabeth Eisenhauer, MD

Blood (2004) 104 (11): 3278.

https://doi.org/10.1182/blood.V104.11.3278.3278

Published: 2004

NARROW

Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom's Macroglobulinemia

Management of Catastrophic Antiphosphopholipid Syndrome with Eculizumab

A Patient with Chronic Lymphocytic Leukemia and Bone Localization: A Case Report

Antitumor Activity of Bortezomib (PS-341; Velcade) in a Phase II Study of Patients with Previously Untreated or Treated Waldenstrom’s Macroglobulinemia (WM).

Email alerts

ASH Publications

American Society of Hematology

Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom's Macroglobulinemia

Management of Catastrophic Antiphosphopholipid Syndrome with Eculizumab

A Patient with Chronic Lymphocytic Leukemia and Bone Localization: A Case Report

Antitumor Activity of Bortezomib (PS-341; Velcade) in a Phase II Study of Patients with Previously Untreated or Treated Waldenstrom’s Macroglobulinemia (WM).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only